RT Journal Article SR Electronic T1 Chromosome 20p11.2 deletions cause congenital hyperinsulinism via the likely disruption of FOXA2 JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.08.16.23294161 DO 10.1101/2023.08.16.23294161 A1 Laver, Thomas W A1 Wakeling, Matthew N A1 Caswell, Richard C A1 Bunce, Benjamin A1 Yau, Daphne A1 Houghton, Jayne AL A1 Hopkins, Jasmin J. A1 Weedon, Michael N A1 Saraff, Vrinda A1 Kershaw, Melanie A1 Honey, Engela M A1 Murphy, Nuala A1 Giri, Dinesh A1 Nath, Stuart A1 Saredo, Ana Tangari A1 Banerjee, Indraneel A1 Hussain, Khalid A1 Owens, Nick DL A1 Flanagan, Sarah E YR 2023 UL http://medrxiv.org/content/early/2023/08/21/2023.08.16.23294161.abstract AB Persistent congenital hyperinsulinism (HI) is a rare genetically heterogeneous condition characterised by dysregulated insulin secretion leading to life-threatening hypoglycaemia. For up to 50% of affected individuals screening of the known HI genes does not identify a disease-causing variant. Large deletions have previously been used to identify novel regulatory regions causing HI. Here, we used genome sequencing to search for novel large (>1Mb) deletions in 180 probands with HI of unknown cause and replicated our findings in a large cohort of 883 genetically unsolved individuals with HI using off-target copy number variant calling from targeted gene panels. We identified overlapping heterozygous deletions in five individuals (range 3-8 Mb) spanning chromosome 20p11.2. The pancreatic beta-cell transcription factor gene, FOXA2, a known cause of HI was deleted in two of the five individuals. In the remaining three, we found a minimal deleted region of 2.4 Mb adjacent to FOXA2 that encompasses multiple non-coding regulatory elements that are in conformational contact with FOXA2. Our data suggests that the deletions in these three patients may cause disease through the dysregulation of FOXA2 expression. These findings provide new insights into the regulation of FOXA2 in the beta-cell and confirm an aetiological role for chromosome 20p deletions in syndromic HI.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMaNW is a recipient of an Independent Fellowship and TWL and NO a Lectureship from the Exeter Diabetes Centre of Excellence funded by Research England Expanding Excellence in England fund. SEF is a Wellcome Trust Senior Research Fellow (223187/Z/21/Z). This study was supported by the National Institute for Health and Care Research Exeter Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The North Wales Research Ethics Committee gave ethical approval for this work (517/WA/0327).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll non-clinical data analyzed during this study are included in this article (and its Supplementary Information). Clinical and genotype data can be used to identify individuals and are therefore available only through collaboration to experienced teams working on approved studies examining the mechanisms, cause, diagnosis and treatment of diabetes and other beta cell disorders. Requests for collaboration will be considered by a steering committee following an application to the Genetic Beta Cell Research Bank (https://www.diabetesgenes.org/current-research/genetic-beta-cell-research-bank/). Contact by email should be directed to S. Flanagan (s.flanagan{at}exeter.ac.uk). All requests for access to data will be responded to within 14 d. Accession codes and DOI numbers for all ChIP-seq, ATAC-seq, RNA-seq and scRNA-seq datasets are provided in Supplementary Table 2. We used the Genome Reference Consortium Human Build 37 (GRCh37) to annotate genetic data (accession number GCF_000001405.13). Details of this assembly are provided at https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.13/.